Related content

Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [111In]-labeled CHX-A''DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines

By      

Experimental and Therapeutic Medicine, Vol. 2, Iss. 3, 2011-01 ,pp. : 523-528

Spandidos Publications

Access to resources Recommend Favorite

Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients

By  

Oncology Letters, Vol. 9, Iss. 2, 2015-01 ,pp. : 950-954

Spandidos Publications

Access to resources Recommend Favorite

Targeting HER1/EGFR in cancer therapy: experience with erlotinib

By Giaccone Giuseppe  

Future Oncology, Vol. 1, Iss. 4, 2005-08 ,pp. : 449-460

Future Medicine

Access to resources Recommend Favorite

HER2 and COX2 expression in human prostate cancer

By Edwards J.   Mukherjee R.   Munro A.F.   Wells A.C.   Almushatat A.   Bartlett J.M.S.  

European Journal of Cancer, Vol. 40, Iss. 1, 2004-01 ,pp. : 50-55

Elsevier

Access to resources Recommend Favorite

Prostate cancer cell lines lack amplification: Overexpression of HER2

By Ullén Anders   Lennartsson Lena   Harmenberg Ulrika   Lennernäs Bo   Majumder Khairul   Holmberg Anders   Nilsson Sten   Elmberger Göran  

Acta Oncologica, Vol. 44, Iss. 5, 2005-07 ,pp. : 490-495

Informa Healthcare

Access to resources Recommend Favorite